Low-Dose Clofarabine In Combination With A Standard Remission Induction In Patients Aged 18-60 Years With Previously Untreated Intermediate And Bad-Risk Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome: Combined Phase 1/11 Results Of The Eortc/Gimema Aml-14a Trial